Savara Obtains Global Rights to Develop and Commercialize Apulmiq

Go back to Savara Obtains Global Rights to Develop and Commercialize Apulmiq
(NASDAQ: SVRA) Delayed: 5.83 +0.05 (0.87%)
Previous Close $5.78    52 Week High
Open $5.83    52 Week Low
Day High $5.93    P/E N/A 
Day Low $5.71    EPS
Volume 1,897,595